Back to Top

FOR SOME PATIENTS

Uncontrolled Gout Can Go On and On and On

Whether you call it severe gout, chronic gout, tophaceous gout, or uncontrolled gout, the challenges your patients are facing with persistently high serum uric acid (sUA) levels can
go beyond debilitating flares and tophi.

This systemic, progressive disease continues to form and deposit monosodium urate (MSU) crystals throughout the body, which can negatively impact organ systems and patients’ daily lives.1-7

mobile campaign image
sUA levels higher or equal to 6 mg/dL despite treatment icon

About Uncontrolled Gout

When a patient experiences persistent, sustained sUA levels of >6 mg/dL despite urate-lowering therapy and 2 or more flares a year or non-resolving tophi, these are warning signs of something much deeper.1,5,8

Uncontrolled, chronic gout inflammation icon

The Full Impact of Uncontrolled Gout

The effects of uncontrolled gout can reach beyond the joints. See how this systemic and progressive condition is linked to chronic inflammation, comorbidities, and daily challenges.1,2,7

Uncontrolled, chronic gout treatment icon

Managing Uncontrolled Gout

The current urate-lowering therapies to treat uncontrolled gout are often underdosed and underutilized. Additional options are needed to help address the progressive nature of the disease.8-11

updates icon

Sign Up for Updates

Be the first to know about our updates in uncontrolled gout.

Sign Up Now

The information provided on this website is intended for healthcare professionals (HCPs) for informational and educational purposes only. It is not intended to replace the independent clinical judgment of HCPs in diagnosing or treating individual patients.

References

1. Francis-Sedlak M, et al. Rheumatol Ther. 2021;8(1):183-197. 2. Dalbeth N, et al. Lancet. 2021;397(10287):1843-1855. 3. Brook RA, et al. Curr Med Res Opin. 2010;26(12):2813-2821. 4. Perez-Ruiz F, et al. Ann Rheum Dis. 2014;73(1):177-182. 5. Morlock RJ, et al. Rheumatol Ther. 2025;12(1):37-51. 6. Timsans J, et al. J Clin Med. 2024;13(24):7616. 7. Edwards NL, et al. J Med Econ. 2011;14(1):10-15. 8. FitzGerald JD, et al. Arthritis Care Res (Hoboken). 2020;72(6):744-760. 9. Schlesinger N, et al. Nat Rev Rheumatol. 2023;19(10):640-649. 10. Richette P, et al. Ann Rheum Dis. 2017;76(1):29-42. 11. Data on File. Sobi, Inc. 2023.